GlobeNewswire Inc.··NaCelldex Raises $300M to Fuel Barzolvolimab Launch and Pipeline Expansion
Celldex prices $300M stock offering at $29/share to fund commercial launch of CSU treatment and expand bispecific antibody platform.
CLDXbarzolvolimabclinical development